Robert C Gallo

List of Publications by Year in Descending Order

159 papers	20,065 citations	61 h-index	141 g-index
178 ext. papers	21,254 ext. citations	22.3 avg, IF	6.28 L-index

#	Paper	IF	Citations
159	Use of oral polio vaccine and the incidence of COVID-19 in the world.. *PLoS ONE*, **2022**, 17, e0265562	3.7	1
158	Reflections on Some of the Exceptional Features of HTLV-1 and HTLV-1 Research: A Perspective.. *Frontiers in Immunology*, **2022**, 13, 859654	8.4	
157	COVID-19 Infection Among Women in Iran Exposed vs Unexposed to Children Who Received Attenuated Poliovirus Used in Oral Polio Vaccine. *JAMA Network Open*, **2021**, 4, e2135044	10.4	2
156	Evolution toward beta common chain receptor usage links the matrix proteins of HIV-1 and its ancestors to human erythropoietin. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	2
155	Viruses and Bacteria Associated with Cancer: An Overview. *Viruses*, **2021**, 13,	6.2	4
154	Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	29
153	Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. *Vaccine*, **2021**, 39, 3879-3891	4.1	2
152	Tampering of Viruses and Bacteria with Host DNA Repair: Implications for Cellular Transformation. *Cancers*, **2021**, 13,	6.6	4
151	Letter to the Editor. *Risk Analysis*, **2021**, 41, 387-388	3.9	2
150	Exogenous bacterial DnaK increases protein kinases activity in human cancer cell lines. *Journal of Translational Medicine*, **2021**, 19, 60	8.5	2
149	Variability of CD4+ Cell Counts in HIV-1-Uninfected Volunteers Who Are Eligible for a Phase I HIV Vaccine Study. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2020**, 84, 37-44	3.1	1
148	Can existing live vaccines prevent COVID-19?. *Science*, **2020**, 368, 1187-1188	33.3	60
147	Inverse correlation between average monthly high temperatures and COVID-19-related death rates in different geographical areas. *Journal of Translational Medicine*, **2020**, 18, 251	8.5	18
146	Role of Mycoplasma Chaperone DnaK in Cellular Transformation. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	8
145	Emerging of a SARS-CoV-2 viral strain with a deletion in nsp1. *Journal of Translational Medicine*, **2020**, 18, 329	8.5	43
144	Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. *Journal of Translational Medicine*, **2020**, 18, 179	8.5	558
143	HIV/AIDS Research for the Future. *Cell Host and Microbe*, **2020**, 27, 499-501	23.4	3

142	40 years of the human T-cell leukemia virus: past, present, and future. *F1000Research*, **2019**, 8,	3.6	37
141	Microenvironment tailors nTreg structure and function. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 6298-6307	11.5	14
140	Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response. *Journal of Clinical Investigation*, **2019**, 129, 1314-1328	15.9	23
139	Proteome analysis of Mycoplasma fermentans cultured under aerobic and anaerobic conditions. *Translational Medicine Communications*, **2019**, 4,	4	3
138	Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E4453-E4462	11.5	15
137	Time to eradicate HTLV-1: an open letter to WHO. *Lancet, The*, **2018**, 391, 1893-1894	40	60
136	Mycoplasma promotes malignant transformation in vivo, and its DnaK, a bacterial chaperone protein, has broad oncogenic properties. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E12005-E12014	11.5	30
135	Characterization of cytopathic factors through genome-wide analysis of the Zika viral proteins in fission yeast. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E376-E385	11.5	41
134	Patterns of conserved gp120 epitope presentation on attached HIV-1 virions. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E9893-E9902	11.5	7
133	Anti-inflammatory effects of HS during acute bacterial infection: a review. *Journal of Translational Medicine*, **2017**, 15, 100	8.5	47
132	Reducing the global burden of HTLV-1 infection: An agenda for research and action. *Antiviral Research*, **2017**, 137, 41-48	10.8	81
131	The Exceptional Oncogenicity of HTLV-1. *Frontiers in Microbiology*, **2017**, 8, 1425	5.7	41
130	Time to Go Back to the Original Name. *Frontiers in Microbiology*, **2017**, 8, 1800	5.7	8
129	Extracellular vesicles and viruses: Are they close relatives?. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 9155-61	11.5	246
128	Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 13168-13173	11.5	21
127	An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques. *Vaccine Journal*, **2016**, 23, 618-27		6
126	Screening transplant donors for HTLV-1 and -2. *Blood*, **2016**, 128, 3029-3031	2.2	28
125	Shock and kill with caution. *Science*, **2016**, 354, 177-178	33.3	15

124	Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E992-9	11.5	98
123	Developing a Successful HIV Vaccine. *Journal of Infectious Diseases*, **2015**, 212 Suppl 1, S40-1	7	2
122	Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 9412-7	11.5	63
121	Angiogenic, lymphangiogenic and adipogenic effects of HIV-1 matrix protein p17. *Pathogens and Disease*, **2015**, 73, ftv062	4.2	12
120	Modulating the durability of anti-HIV gp120 antibody responses after vaccination: a comment on Wilson & Karp (2015). *Philosophical Transactions of the Royal Society B: Biological Sciences*, **2015**, 370,	5.8	2
119	A historical personal perspective on human retroviruses and their infection of T cells. *Transfusion*, **2015**, 55, 1-9	2.9	1
118	Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 14331-6	11.5	45
117	Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 15614-21	11.5	74
116	HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. *Virology*, **2014**, 471-473, 81-92	3.6	19
115	The Global Virus Network's testimony on Ebola to the U.S. Senate. *F1000Research*, **2014**, 3, 307	3.6	
114	Research and discovery of the first human cancer virus, HTLV-1. *Best Practice and Research in Clinical Haematology*, **2011**, 24, 559-65	4.2	30
113	Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 20476-81	11.5	56
112	Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 2489-96	5.9	30
111	Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 17477-82	11.5	70
110	A perspective on human herpes virus 6 (HHV-6). *Journal of Clinical Virology*, **2006**, 37 Suppl 1, S2	14.5	2
109	A reflection on HIV/AIDS research after 25 years. *Retrovirology*, **2006**, 3, 72	3.6	55
108	The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years. *Lancet, The*, **2005**, 366, 1894-8	40	44
107	Commentary remarks on "HIV/AIDS in China". *Cell Research*, **2005**, 15, 823	24.7	

106	History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2. *Oncogene*, **2005**, 24, 5926-30	9.2	97
105	Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 14807-12	11.5	124
104	HIV-1: a look back from 20 years. *DNA and Cell Biology*, **2004**, 23, 191-2	3.6	2
103	The discovery of HIV as the cause of AIDS. *New England Journal of Medicine*, **2003**, 349, 2283-5	59.2	164
102	A journey with T cells, primate/human retroviruses and other persisting human T-cell tropic viruses. *Reviews in Clinical and Experimental Hematology*, **2003**, 7, 329-35		
101	Human retroviruses after 20 years: a perspective from the past and prospects for their future control. *Immunological Reviews*, **2002**, 185, 236-65	11.3	44
100	HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 9972-7	11.5	56
99	HIV infection and pathogenesis: what about chemokines?. *Journal of Clinical Immunology*, **1999**, 19, 293-9	5.7	26
98	Kaposi's Sarcoma: Correction. *Science*, **1999**, 283, 1115-1115	33.3	
97	Chemokine receptors and chemokines in HIV infection. *Journal of Clinical Immunology*, **1998**, 18, 243-55	5.7	25
96	Effects of a urinary factor from women in early pregnancy on HIV-1, SIV and associated disease. *Nature Medicine*, **1998**, 4, 428-34	50.5	52
95	Reply to "Anti-KS activity still a mystery" *Nature Medicine*, **1998**, 4, 748-748	50.5	
94	CD4 promoter transactivation by human herpesvirus 6. *Journal of Virology*, **1998**, 72, 8797-805	6.6	34
93	Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. *Nature Medicine*, **1997**, 3, 651-8	50.5	149
92	The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. *Nature Medicine*, **1996**, 2, 1244-7	50.5	457
91	HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. *Nature Medicine*, **1995**, 1, 321-9	50.5	63
90	Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. *Nature Medicine*, **1995**, 1, 667-73	50.5	83
89	Human retroviruses in the second decade: a personal perspective. *Nature Medicine*, **1995**, 1, 753-9	50.5	28

88	Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. *Nature*, **1995**, 375, 64-8	50.4	196
87	Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. *Nature*, **1994**, 371, 674-80	50.4	517
86	Infection of the central nervous system by human retroviruses. *Annals of the New York Academy of Sciences*, **1994**, 724, 125-32	6.5	1
85	Human herpesvirus 7 (HHV-7) strain JI: independent confirmation of HHV-7. *Journal of Infectious Diseases*, **1992**, 166, 690-1	7	60
84	Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma. *Immunological Reviews*, **1992**, 127, 147-55	11.3	132
83	Induction of CD4 and susceptibility to HIV-1 infection in human CD8+ T lymphocytes by human herpesvirus 6. *Nature*, **1991**, 349, 533-5	50.4	224
82	Sequence analysis of original HIV-1. *Nature*, **1991**, 349, 745-6	50.4	12
81	Gallo's virus sequence. *Nature*, **1991**, 351, 358	50.4	2
80	. . . and his response. *Nature*, **1991**, 351, 358-358	50.4	1
79	Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. *Nature*, **1990**, 345, 84-6	50.4	817
78	Kaposi's sarcoma and AIDS. *Nature*, **1990**, 346, 801-802	50.4	2
77	Human retroviruses: cancer and AIDS. *International Journal of Cancer*, **1989**, 4, 2-5	7.5	3
76	Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6. *Nature*, **1989**, 337, 370-3	50.4	286
75	Proliferative T-Cell Response to HIV Envelope Glycoprotein in Immunized and Infected Primates and Human Beings. *Journal of Medical Primatology*, **1989**, 18, 363-369	0.7	5
74	Geographic distribution of HTLV-I and identification of a new high-risk population. *International Journal of Cancer*, **1988**, 42, 7-12	7.5	72
73	Utilization of human hematopoietic cell lines for the propagation and characterization of HBLV (human herpesvirus 6). *International Journal of Cancer*, **1988**, 42, 787-91	7.5	133
72	Biologically diverse molecular variants within a single HIV-1 isolate. *Nature*, **1988**, 334, 444-7	50.4	248
71	Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. *Nature*, **1988**, 334, 706-8	50.4	139

70	Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers. *Science*, **1988**, 239, 68-71	33.3	160
69	Relationship between HTLV-III neutralizing antibody and clinical status of pediatric acquired immunodeficiency syndrome (AIDS) and AIDS-related complex cases. *Pediatric Research*, **1987**, 21, 547-50	3.2	35
68	Human retroviruses: HTLV-I, II, and III and their association with leukemia and AIDS. *Annals of the New York Academy of Sciences*, **1987**, 511, 350-69	6.5	3
67	New human and simian HIV-related retroviruses possess functional transactivator (tat) gene. *Nature*, **1987**, 328, 548-50	50.4	83
66	Hydrocortisone and some other hormones enhance the expression of HTLV-III. *International Journal of Cancer*, **1986**, 37, 67-72	7.5	107
65	STLV-I antibodies in feral populations of East African vervet monkeys (Cercopithecus aethiops). *International Journal of Cancer*, **1986**, 38, 523-9	7.5	47
64	Origins of human T-lymphotropic viruses. *Nature*, **1986**, 320, 219	50.4	11
63	The trans-activator gene of HTLV-III is essential for virus replication. *Nature*, **1986**, 320, 367-71	50.4	589
62	Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. *Nature*, **1986**, 320, 535-7	50.4	225
61	First isolation of HTLV-III. *Nature*, **1986**, 321, 119-119	50.4	13
60	Reply to: Lack of evidence for involvement of known human retroviruses in multiple sclerosis. *Nature*, **1986**, 322, 178-178	50.4	6
59	Molecular biology of terminal transferase. *Critical Reviews in Biochemistry*, **1986**, 21, 27-52		54
58	Occurrence of HTLV-I antibodies in Danish patients with cutaneous T-cell lymphoma. *Scandinavian Journal of Haematology*, **1985**, 34, 455-62		14
57	Complete nucleotide sequence of the AIDS virus, HTLV-III. *Nature*, **1985**, 313, 277-84	50.4	2162
56	HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. *Nature*, **1985**, 316, 72-4	50.4	411
55	A molecular clone of HTLV-III with biological activity. *Nature*, **1985**, 316, 262-5	50.4	304
54	Human T-lymphotropic retroviruses. *Nature*, **1985**, 317, 395-403	50.4	591
53	Multiple sclerosis and human T-cell lymphotropic retroviruses. *Nature*, **1985**, 318, 154-60	50.4	328

52	Seroepidemiology of human T-lymphotropic retrovirus type I (HTLV-I) in residents of Niigata Prefecture, Japan. Comparative studies by indirect immunofluorescence microscopy and enzyme-linked immunosorbent assay. *International Journal of Cancer*, **1985**, 35, 301-6	7.5	15
51	Seroepidemiologic studies of human T-cell leukemia/lymphoma virus type I in Jamaica. *International Journal of Cancer*, **1985**, 36, 37-41	7.5	73
50	Human T-cell leukemia (lymphotropic) retroviruses and their causative role in T-cell malignancies and acquired immune deficiency syndrome. *Cancer*, **1985**, 55, 2317-23	6.4	18
49	Molecular and immunologic analysis of a chronic lymphocytic leukemia case with antibodies against human T-cell leukemia virus. *Cancer*, **1985**, 56, 495-9	6.4	17
48	HTLV-III infection in brains of children and adults with AIDS encephalopathy. *Science*, **1985**, 227, 177-82	33.3	843
47	Retroviruses in human T-cell malignancies. *Cancer Investigation*, **1984**, 2, 467-78	2.1	
46	Isolation of HTLV-transformed B-lymphocyte clone from a patient with HTLV-associated adult T-cell leukaemia. *Nature*, **1984**, 310, 505-6	50.4	99
45	Transformation of NIH 3T3 cells by a human c-sis cDNA clone. *Nature*, **1984**, 308, 464-7	50.4	182
44	Molecular cloning and characterization of the HTLV-III virus associated with AIDS. *Nature*, **1984**, 312, 166-9	50.4	309
43	Transformation of different phenotypic types of human bone marrow T-lymphocytes by HTLV-1. *International Journal of Cancer*, **1984**, 33, 13-7	7.5	69
42	Location of human T-cell leukemia virus (HTLV) p19 antigen on virus-producing cells. *International Journal of Cancer*, **1984**, 33, 161-5	7.5	13
41	Natural antibodies to human T-cell leukemia/lymphoma virus in healthy Venezuelan populations. *International Journal of Cancer*, **1984**, 34, 501-6	7.5	73
40	Molecular cloning and analysis of a new variant of human T-cell leukemia virus (HTLV-ib) from an African patient with adult T-cell leukemia-lymphoma. *International Journal of Cancer*, **1984**, 34, 613-8	7.5	57
39	Antibody to human T cell leukaemia virus type III in Australian homosexual men with lymphadenopathy. *Medical Journal of Australia*, **1984**, 141, 274-6	4	8
38	Retroviruses in human leukemia. *Hematological Oncology*, **1983**, 1, 193-204	1.3	7
37	Persistent in vitro infection by human T-cell leukemia-lymphoma virus (HTLV) of normal human T-lymphocytes from blood relatives of patients with HTLV-associated mature T-cell neoplasms. *International Journal of Cancer*, **1983**, 31, 171-80	7.5	37
36	Infection and transformation of fresh human umbilical cord blood cells by multiple sources of human T-cell leukemia-lymphoma virus (HTLV). *International Journal of Cancer*, **1983**, 31, 413-20	7.5	105
35	Antibodies against human T-cell leukemia/lymphoma virus (HTLV) and expression of HTLV p19 antigen in relatives of a T-cell leukemia patient originating from Surinam. *International Journal of Cancer*, **1983**, 32, 337-42	7.5	22

34	Antibodies against three purified structural proteins of the human type-C retrovirus, HTLV, in Japanese adult T-cell leukemia patients, healthy family members, and unrelated normals. *International Journal of Cancer*, **1983**, 32, 583-90	7.5	15
33	Complete amino acid sequence of human T-cell leukemia virus structural protein p15. *FEBS Letters*, **1983**, 162, 390-5	3.8	62
32	A survey of human leukaemias for sequences of a human retrovirus. *Nature*, **1983**, 302, 626-8	50.4	187
31	Common site of integration of HTLV in cells of three patients with mature T-cell leukaemia-lymphoma. *Nature*, **1983**, 303, 253-6	50.4	17
30	Nucleotide sequence of cloned cDNA of human c-myc oncogene. *Nature*, **1983**, 303, 725-8	50.4	296
29	Chromosomal sublocalization of human c-myb and c-fes cellular onc genes. *Nature*, **1983**, 304, 169-71	50.4	164
28	Common site of integration of HTLV in cells of three patients with mature T-cell leukaemia-lymphoma: a retraction. *Nature*, **1983**, 305, 340	50.4	15
27	Association of human T-cell leukaemia/lymphoma virus with the Tac antigen marker for the human T-cell growth factor receptor. *Nature*, **1983**, 305, 733-6	50.4	82
26	The human type-C retrovirus, HTLV, in Blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma. *International Journal of Cancer*, **1982**, 30, 257-64	7.5	489
25	Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. *Nature*, **1982**, 295, 116-9	50.4	478
24	Onc gene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patient. *Nature*, **1982**, 299, 61-3	50.4	594
23	Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. *Virology*, **1981**, 112, 355-60	3.6	267
22	A human onc gene homologous to the transforming gene (v-sis) of simian sarcoma virus. *Nature*, **1981**, 292, 31-5	50.4	158
21	Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with S□ary T-cell leukaemia. *Nature*, **1981**, 294, 268-71	50.4	647
20	The v-sis transforming gene of simian sarcoma virus is a new onc gene of primate origin. *Nature*, **1981**, 294, 273-5	50.4	48
19	Human T-cell growth factor: parameters for production. *Journal of Supramolecular Structure*, **1980**, 13, 229-41		23
18	Placenta-bound immunoglobulins. *Arthritis and Rheumatism*, **1979**, 22, 1308-13		7
17	Surface antibodies of human myelogenous leukaemia leukocytes reactive with specific type-C viral reverse transcriptases. *Nature*, **1978**, 276, 230-6	50.4	36

16	Antigenic characterization of a new gibbon ape leukemia virus isolate: seroepidemiologic assessment of an outbreak of gibbon leukemia. *International Journal of Cancer*, **1978**, 22, 715-20	7.5	20
15	Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. *Nature*, **1977**, 270, 347-9	50.4	1767
14	Proviral sequences of baboon endogenous type C RNA virus in DNA of human leukaemic tissues. *Nature*, **1976**, 262, 190-5	50.4	57
13	Infective transmission and characterisation of a C-type virus released by cultured human myeloid leukaemia cells. *Nature*, **1975**, 256, 551-5	50.4	109
12	The evidence for involvement of type C RNA tumor viruses in human acute leukemia. *Cancer*, **1974**, 34, suppl:1398-405	6.4	14
11	Immunological relationship of DNA polymerase from human acute leukaemia cells and primate and mouse leukaemia virus reverse transcriptase. *Nature*, **1973**, 244, 206-9	50.4	131
10	Purification, characterization, and comparison of the DNA polymerases from two primate RNA tumor viruses. *Journal of Virology*, **1973**, 12, 431-9	6.6	122
9	Chromatographic analyses of isoaccepting tRNAs from avian myeloblastosis virus. *Journal of Virology*, **1973**, 12, 449-57	6.6	20
8	Selective Toxicity of Rifamycin Derivatives for Leukaemic Human Leucocytes. *Nature: New Biology*, **1972**, 236, 166-171		37
7	Reverse transcriptase, RNA tumour virus transformation and derivatives of rifamycin SV. *Nature: New Biology*, **1972**, 236, 163-6		56
6	RNA of RNA Tumour Viruses contains Poly A. *Nature: New Biology*, **1972**, 236, 227-231		183
5	Reverse transcriptase activity of human acute leukaemic cells: purification of the enzyme, response to AMV 70S RNA, and characterization of the DNA product. *Nature: New Biology*, **1972**, 240, 67-72		143
4	Asparaginyl-tRNA and resistance of murine leukaemias to L-asparaginase. *Nature*, **1970**, 227, 1134-6	50.4	15
3	RNA dependent DNA polymerase of human acute leukaemic cells. *Nature*, **1970**, 228, 927-9	50.4	248
2	Transfer RNA's in human leukemia. *Journal of Cellular Physiology*, **1969**, 74, Suppl 1:149+	7	37
1	Human Retroviruses in the Second Decade: Some Pathogenic Mechanisms and Approaches to Their Control		245-269